Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-2027
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France ; volume:34 ; number:4 ; day:16 ; month:2 ; year:2016 ; pages:363-391 ; date:4.2016
PharmacoEconomics ; 34, Heft 4 (16.2.2016), 363-391, 4.2016
- Creator
-
Druais, Sylvain
- Contributor
-
Doutriaux, Agathe
Cognet, Magali
Godet, Annabelle
Lancon, Christophe
Lévy, Pierre
Samalin, Ludovic
Guillon, Pascal
SpringerLink (Online service)
- DOI
-
10.1007/s40273-015-0348-x
- URN
-
urn:nbn:de:1111-2016032045857
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 1:02 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Druais, Sylvain
- Doutriaux, Agathe
- Cognet, Magali
- Godet, Annabelle
- Lancon, Christophe
- Lévy, Pierre
- Samalin, Ludovic
- Guillon, Pascal
- SpringerLink (Online service)
Other Objects (12)
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Long-Acting Injectable Antipsychotics in a Prescription Claims Data Source: A Validation Study
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review
All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis